Scholarlink

<p>A clinical trial of a multi-strain vaginal synbiotic (NCT05659745, registered 12/19/2022 at clinicaltrials.gov) led to an optimal vaginal microbiome dominated by <i>L. crispatus</i> (CST I). The synbiotic led to a significant increase in <i>L. crispatus</i> compared to placebo (<i>p</i> &lt; 0.05), and conversion to CST I was significantly higher with the vaginal synbiotic than with placebo (90 vs 11%; <i>p</i> &lt; 0.002). Mechanistically, the synbiotic reduced <i>Gardnerella vaginalis</i> and <i>Candida</i>, clinically important microbes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of a multi-strain L. crispatus-based vaginal synbiotic on the vaginal microbiome: a randomized placebo-controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月9日

查看全文
  • Jacques Ravel,
  • Sheri Simmons,
  • Eleni Greenwood Jaswa,
  • Sara Gottfried,
  • Miriam Greene,
  • Susan Kellogg-Spadt,
  • Dirk Gevers,
  • Diane M. Harper

摘要

A clinical trial of a multi-strain vaginal synbiotic (NCT05659745, registered 12/19/2022 at clinicaltrials.gov) led to an optimal vaginal microbiome dominated by L. crispatus (CST I). The synbiotic led to a significant increase in L. crispatus compared to placebo (p < 0.05), and conversion to CST I was significantly higher with the vaginal synbiotic than with placebo (90 vs 11%; p < 0.002). Mechanistically, the synbiotic reduced Gardnerella vaginalis and Candida, clinically important microbes.